Lidakol n-docosanol 10 percent cream data

LDAKA (La Jolla, Calif.) announced Phase III results from a European trial comparing Lidakol to acyclovir 5 percent cream.

Comparable results were obtained on the primary end point, time to healing, in 326 patients. Comparable activity to an existing drug satisfies one criterion for registration in many European countries, the company said. ...